These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15462176)

  • 1. Monoamine oxidase inhibitors, their structural analogues, and neuroprotection.
    Sowa BN; Holt A; Todd KG; Baker GB
    Indian J Exp Biol; 2004 Sep; 42(9):851-7. PubMed ID: 15462176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase inhibitors and neuroprotection: a review.
    Al-Nuaimi SK; Mackenzie EM; Baker GB
    Am J Ther; 2012 Nov; 19(6):436-48. PubMed ID: 22960850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on amine oxidase inhibitors: multifaceted drugs.
    Song MS; Matveychuk D; MacKenzie EM; Duchcherer M; Mousseau DD; Baker GB
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():118-24. PubMed ID: 23410524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Baker GB; Sowa B; Todd KG
    J Psychiatry Neurosci; 2007 Sep; 32(5):313-5. PubMed ID: 17823646
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A neglected modality in psychiatric treatment--the monoamine oxidase inhibitors.
    Johnson WC
    Dis Nerv Syst; 1975 Sep; 36(9):521-5. PubMed ID: 1175468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S; Weinreb O; Amit T; Youdim MB
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoamine oxidase inhibitors: various clinical remarks on phenelzine].
    Guyotat J; Favre-Tissot M; Marie-Cardine M
    J Med Lyon; 1966 Jun; 47(101):1009-15. PubMed ID: 4914860
    [No Abstract]   [Full Text] [Related]  

  • 12. [Phenelzine: legacy or current psychiatric practice?].
    Marini S; Serata D; Brugnoli R
    Clin Ter; 2013; 164(3):e211-22. PubMed ID: 23868641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
    Pálfi M; Szökó E; Kálmán M
    Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection by rasagiline in thiamine deficient rats.
    Eliash S; Dror V; Cohen S; Rehavi M
    Brain Res; 2009 Feb; 1256():138-48. PubMed ID: 19103184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression].
    Nolen WA
    Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1940-3. PubMed ID: 14574774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
    McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
    Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.